Gyre Therapeutics, Inc. Current Portion of Long-Term Debt
Gyre Therapeutics, Inc. (GYRE) had Current Portion of Long-Term Debt of $478.00 thousand as of 2014-09-30, per its 10-Q filed 2014-11-06.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Long-Term Debt, Current Maturities
us-gaap:LongTermDebtCurrent · last filed 2015-03-16
- 2014-09-30: Long-term Debt, Current Maturities $478.00K.
- 2014-06-30: Long-term Debt, Current Maturities $699.00K.
- 2014-03-31: Long-term Debt, Current Maturities $776.00K.
- 2013-12-31: Long-term Debt, Current Maturities $853.00K.
| Period end | Long-term Debt, Current Maturities |
|---|---|
| 2014-09-30 | $478.00K 10-Q · filed 2014-11-06 |
| 2014-06-30 | $699.00K 10-Q · filed 2014-08-07 |
| 2014-03-31 | $776.00K 10-Q · filed 2014-05-08 |
| 2013-12-31 | $853.00K 10-K · filed 2015-03-16 |
| 2013-09-30 | $873.00K 10-Q · filed 2013-11-06 |
| 2013-06-30 | $866.00K 10-Q · filed 2013-08-07 |
| 2013-03-31 | $858.00K 10-Q · filed 2013-05-08 |
| 2012-12-31 | $851.00K 10-K · filed 2014-03-14 |
| 2012-09-30 | $844.00K 10-Q · filed 2012-11-08 |
| 2012-06-30 | $870.00K 10-Q · filed 2012-08-09 |
| 2012-03-31 | $896.00K 10-Q · filed 2012-05-09 |
| 2011-12-31 | $1.24M 10-K · filed 2013-03-15 |
| 2011-09-30 | $1.59M 10-Q · filed 2011-11-03 |
| 2011-06-30 | $1.91M 10-Q · filed 2011-08-09 |
| 2010-12-31 | $1.71M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |